glp-1 agonists blindness risk GLP 1 Doctor Explains GLP 1 Blindness
Description
Drug designers are creating multi-agonists that stimulate more than one receptor, potentially amplifying results

There are also concerns that long-term usage of GLP-1 RAs may cause pancreatitis or even lead to the development of pancreatic cancer

Accepted 2021-4-28

Route, form, and dosage: Saxenda comes in a self-injectable pen

Methods We searched for eligible trials published in PubMed (last search in February 2015) by using the following search algorithm: (Glucagon-like peptide-1 receptor agonists OR exenatide OR liraglutide OR lixisenatide OR albiglutide OR dulaglutide) AND (side effects OR adverse effects OR safety OR gastrointestinal OR pancreas OR liver OR cardiovascular OR skin OR allergy OR angioedema OR immune system OR renal OR kidney OR infection OR central nervous system OR blood OR malignancy OR cancer) The search was limited by the following criteria: - Published in the English language

Patients with T2DM and obesity exhibit an elevated risk of adverse cardiovascular events
